Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases. / Nielsen, Valdemar Wendelboe; Yao, Yiqiu; Egeberg, Alexander; Thomsen, Simon Francis.

I: Drugs of the Future, Bind 48, Nr. 3, 2023, s. 165-172.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Nielsen, VW, Yao, Y, Egeberg, A & Thomsen, SF 2023, 'Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases', Drugs of the Future, bind 48, nr. 3, s. 165-172. https://doi.org/10.1358/dof.2023.48.3.3500035

APA

Nielsen, V. W., Yao, Y., Egeberg, A., & Thomsen, S. F. (2023). Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases. Drugs of the Future, 48(3), 165-172. https://doi.org/10.1358/dof.2023.48.3.3500035

Vancouver

Nielsen VW, Yao Y, Egeberg A, Thomsen SF. Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases. Drugs of the Future. 2023;48(3):165-172. https://doi.org/10.1358/dof.2023.48.3.3500035

Author

Nielsen, Valdemar Wendelboe ; Yao, Yiqiu ; Egeberg, Alexander ; Thomsen, Simon Francis. / Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases. I: Drugs of the Future. 2023 ; Bind 48, Nr. 3. s. 165-172.

Bibtex

@article{6409744808624ac9bafcff0ccf0d226c,
title = "Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases",
abstract = "The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.",
keywords = "Spesolimab, BI-655130, MAB-92, Generalized pustular psoriasis, IL-36R, Monoclonal antibody",
author = "Nielsen, {Valdemar Wendelboe} and Yiqiu Yao and Alexander Egeberg and Thomsen, {Simon Francis}",
year = "2023",
doi = "10.1358/dof.2023.48.3.3500035",
language = "English",
volume = "48",
pages = "165--172",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "3",

}

RIS

TY - JOUR

T1 - Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

AU - Nielsen, Valdemar Wendelboe

AU - Yao, Yiqiu

AU - Egeberg, Alexander

AU - Thomsen, Simon Francis

PY - 2023

Y1 - 2023

N2 - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

AB - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

KW - Spesolimab

KW - BI-655130

KW - MAB-92

KW - Generalized pustular psoriasis

KW - IL-36R

KW - Monoclonal antibody

U2 - 10.1358/dof.2023.48.3.3500035

DO - 10.1358/dof.2023.48.3.3500035

M3 - Journal article

VL - 48

SP - 165

EP - 172

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 3

ER -

ID: 340531009